Bevacizumab as a treatment option in advanced renal cell carcinoma: an analysis and interpretation of clinical trial data

Cancer Treatment Reviews
David F McDermott, Daniel J George

Abstract

The availability of molecularly targeted agents has improved outcomes for patients with renal cell carcinoma (RCC), a disease long considered refractory to systemic therapy. The hypervascularity observed in RCC tumors, which is driven by the inactivation of the vonHippel-Lindau gene, provided a rationale for targeting angiogenesis, in particular vascular endothelial growth factor (VEGF). Bevacizumab, a potent and specific anti-VEGF monoclonal antibody, has demonstrated significant clinical benefits when used in combination with interferon-alfa (IFN-alpha) for the treatment of metastatic RCC in two randomized phase III trials. The use of bevacizumab with IFN-alpha received approval in Europe for the first-line treatment of patients with advanced or metastatic RCC, and more recently this combination was approved for use in patients with mRCC in the United States. Bevacizumab with IFN-alpha has also been recommended by the National Comprehensive Cancer Network for first-line therapy of relapsed or metastatic unresectable RCC with predominantly clear cell histology. Two phase II studies suggest that bevacizumab has single-agent activity, which is characterized by encouraging progression-free survival rates and evidence of tumor reg...Continue Reading

References

Apr 1, 1989·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·K A MargolinM Roper
Mar 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G FyfeA C Louie
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R J MotzerJ Ferrara
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S PyrhönenP L Kellokumpu-Lehtinen
Jun 2, 2000·Virchows Archiv : an International Journal of Pathology·V ParadisP Bedossa
Mar 29, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·John R JohnsonRichard Pazdur
Aug 2, 2003·The New England Journal of Medicine·Daniel J George, William G Kaelin
Aug 2, 2003·The New England Journal of Medicine·James C YangSteven A Rosenberg
Sep 28, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·James C Yang
Dec 22, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·William Y Kim, William G Kaelin
Jan 28, 2005·The Cochrane Database of Systematic Reviews·C CoppinT Wilt
Oct 6, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·John D HainsworthAnthony Greco
Jun 8, 2006·JAMA : the Journal of the American Medical Association·Robert J MotzerM Dror Michaelson
Dec 13, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·John S LamRobert A Figlin
Dec 13, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Marina PartonTim Eisen
Jan 12, 2007·The New England Journal of Medicine·Robert J MotzerRobert A Figlin
Jan 12, 2007·The New England Journal of Medicine·Bernard EscudierUNKNOWN TARGET Study Group
May 12, 2007·European Urology·Paul C M S Verhagen
May 25, 2007·Nature Reviews. Cancer·Henk M W Verheul, Herbert M Pinedo
Jun 1, 2007·The New England Journal of Medicine·Gary HudesUNKNOWN Global ARCC Trial
Aug 10, 2007·Journal of the National Cancer Institute·Frank A ScappaticciHerbert Hurwitz
Sep 19, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ronald M BukowskiDavid McDermott
Dec 18, 2007·Lancet·Tammy F ChuMing Hui Chen
Apr 15, 2008·Annals of Oncology : Official Journal of the European Society for Medical Oncology·B MelicharB Escudier
Aug 2, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nilofer S AzadElise C Kohn
Aug 2, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Brian I RiniDaniel J George
Oct 22, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Brian I RiniEric J Small
Feb 20, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Darren R FeldmanRobert J Motzer
Feb 24, 2009·Cancer Treatment Reviews·Manuela Schmidinger, Christoph C Zielinski
Apr 25, 2009·BJU International·Joaquim BellmuntStéphane Oudard
May 19, 2009·The Journal of Urology·M P SablinB Escudier
Jul 29, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eric JonaschNizar Tannir
Nov 7, 2009·Clinical Genitourinary Cancer·Ana M Molina, Robert J Motzer
Apr 7, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bernard EscudierVesna Sneller
Apr 7, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Brian I RiniEric J Small
Apr 7, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·John D HainsworthRobert Whorf

❮ Previous
Next ❯

Citations

Oct 16, 2014·Drugs·Gillian M Keating
Oct 13, 2012·Medicinal Research Reviews·Rangaiah ShashidharamurthyPeriasamy Selvaraj
Jan 24, 2012·Expert Opinion on Pharmacotherapy·Camillo Porta, Sergio Bracarda
Dec 7, 2017·International Braz J Urol : Official Journal of the Brazilian Society of Urology·Chao WeiZhiqiang Chen
Nov 8, 2018·Australasian Psychiatry : Bulletin of Royal Australian and New Zealand College of Psychiatrists·Venura PalihawadanaSathya Rao
Oct 30, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Michele Del VecchioAndrea Anichini

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.

Related Papers

BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
Amelia B Zelnak, Ruth M O'Regan
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Giuseppe Giaccone
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Robert J Motzer, Ronald M Bukowski
Discovery Medicine
Astrid A M van der VeldtEpie Boven
© 2021 Meta ULC. All rights reserved